FDA Hears From Stakeholders Regarding CBD

June 4, 2019

Norman "Ned" Sharpless, acting commissioner of the Food and Drug Administration, led the agency's first public hearing on CBD products May 31, and raised many questions regarding the safety of the ingredients, according to The Washington Post.

More than 100 stakeholders testified at the hearing, and while they differed in what they believed the regulations should be, they stressed that regulation decisions were urgent, as CBD use has become common.

Written comments on the issue are due July 2, and may be submitted here. Deputy Commissioner  Amy Abernathy is leading a group that will research the legal and public health nature of CBD sales.


Photo by Kimzy Nanney on Unsplash
Kimzy Nanney 1562047 Unsplash

FDA Will Hold Public Hearing May 31 On CBD

May 30, 2019
The Food and Drug Administration will hold a public hearing May 31 regarding products containing cannabis or cannabis-derived compounds, like CBD, The National Law Review reports...
Heather A. Bailey and Darren Grady, two partners at SmithAmundsen LLC

FDA Softening Stance On CBD? What Is In Store For Vending Employers?

May 8, 2019
While many following the rise of the cannabis industry in the United States have seen CBD-infused food and drink products hitting the market, what many may not know is that CBD...
I Stock 1126711628 01

Should You Carry CBD-Enriched Products?

March 18, 2019
Cannabidiol, commonly known simply as CBD, is all the rage. It is being included in everything from supplements to single-serve coffee and tea. There are even plans to create ...